Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

Applied Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: APLT), will participate in the Neuromuscular & Bone Panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston. This participation highlights the company’s ongoing commitment to addressing high unmet medical needs.

The event will be accessible via webcast on their Investor Relations page, with a replay available afterward. Applied Therapeutics is advancing novel drug candidates, including AT-007 for CNS rare metabolic diseases and AT-001 for Diabetic Cardiomyopathy.

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a Neuromuscular & Bone Panel at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 2:10 p.m. ET in Boston.

Webcast information for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic Retinopathy.

To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.

Contacts

Investors:

Maeve Conneighton
(212) 600-1902
appliedtherapeutics@argotpartners.com

Media:

media@appliedtherapeutics.com

Applied Therapeutics, Inc.

FAQ

When will Applied Therapeutics participate in the Cowen Health Care Conference?

Applied Therapeutics will participate on March 8, 2023, at 2:10 p.m. ET.

Where can I watch the Applied Therapeutics conference presentation?

The conference presentation can be accessed via webcast on the Investor Relations page of Applied Therapeutics' website.

What is the focus of Applied Therapeutics' drug development?

Applied Therapeutics focuses on developing novel drug candidates for high unmet medical needs, including CNS rare metabolic diseases and Diabetic Cardiomyopathy.

What are the lead drug candidates of Applied Therapeutics?

The lead drug candidates are AT-007 for CNS rare metabolic diseases and AT-001 for Diabetic Cardiomyopathy.